Please login to the form below

Not currently logged in


This page shows the latest GVHD news and features for those working in and with pharma, biotech and healthcare.

FDA approves first drug to prevent graft-versus-host disease

FDA approves first drug to prevent graft-versus-host disease

The approval is based on data from two trials. In the phase 2 GVHD-1 study, while patients who received Orencia saw a 97% overall survival rate compared to 84% for ... The second trial, a clinical study known as GVHD-2, used real-world data collected by

Latest news

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
Box 1
Strategic commitment
KOL Ambassador Program & Podcast Creation: A Customer Story